Tech Company Financing Transactions

Akarna Therapeutics Funding Round

On 2/17/2016, Akarna Therapeutics announced $15 million in Series B funding from Forbion Capital Partners, New Science Ventures and Third Point.

Transaction Overview

Announced On
2/17/2016
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series B
Investors
Proceeds Purpose
Akarna will use the funds to accelerate the development of its lead FXR agonist drug candidate through human proof-of-concept studies in patients with non-alcoholic steatohepatitis (NASH), a progressive form of fatty-liver disease for which there are no approved therapies.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1012 Second St. 210
Encinitas, CA 92007
USA
Phone
Undisclosed
Email Address
Overview
Akarna Therapeutics is a biopharmaceutical company developing novel small molecule therapeutics that target inflammatory and fibrotic diseases for which there is no approved treatment.
Profile
Akarna Therapeutics LinkedIn Company Profile
Social Media
Akarna Therapeutics Company Twitter Account
Company News
Akarna Therapeutics News
Facebook
Akarna Therapeutics on Facebook
YouTube
Akarna Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Raju Mohan
  Raju Mohan LinkedIn Profile  Raju Mohan Twitter Account  Raju Mohan News  Raju Mohan on Facebook


 

 

Browse more venture capital transactions:

Prev: 2/17/2016: Seven Bridges venture capital transaction
Next: 2/17/2016: Thermedical venture capital transaction

 

Share this article

 


About Database of VC Transactions

We report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary